Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

被引：0

作者：

Derman, Ben A. ^{[1
]}

Kubicki, Tadeusz ^{[2
]}

Simmons, Heidi ^{[3
]}

Afrough, Aimaz ^{[4
]}

Zonder, Jeffrey A. ^{[5
]}

Grinblatt, David L. ^{[6
]}

Anderson, Larry D., Jr. ^{[7
]}

Kin, Andrew ^{[8
]}

Narula, Sunil

Rayani, Shayan ^{[1
]}

Gurbuxani, Sandeep ^{[9
]}

Karrison, Theodore ^{[2
]}

Jiang, Ken ^{[2
]}

Major, Ajay ^{[10
]}

Cooperrider, Jennifer H. ^{[2
]}

Jacob, Allison P. ^{[11
]}

Jakubowiak, Andrzej J. ^{[1
]}

机构：

[1] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Adapt Biotechnol Corp, Seattle, WA USA

[4] UT Southwestern Med Ctr, Dallas, TX USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] NorthShore Univ HealthSyst, Evanston, IL USA

[7] UT Southwestern Med Ctr, Hematol Malignancies & Cellular Therapy, Dallas, TX USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] Univ Chicago, Dept Pathol, Chicago, IL USA

[10] Univ Colorado, Ctr Canc, Aurora, CO USA

[11] Med Affairs, Adapt Biotechnol, Seattle, WA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182410

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study
Derman, Benjamin A.
Kansagra, Ankit
Zonder, Jeffrey
Stefka, Andrew T.
Grinblatt, David L.
Anderson, Larry D., Jr.
Gurbuxani, Sandeep
Narula, Sunil
Rayani, Shayan
Major, Ajay
Kin, Andrew
Jiang, Ken
Karrison, Theodore
Jasielec, Jagoda
Jakubowiak, Andrzej J.
JAMA ONCOLOGY, 2022, 8 (09) : 1278 - 1286
[32] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Wang, Yuqi
Huan, Chen
Hanzhen, Zhang
Zhang, Shanshan
Yuan, Youhai
Feng, Ru
Wei, Yongqiang
Wei, Xiaolei
BLOOD, 2024, 144 : 7031 - 7031
[33] CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB (KDD) VERSUS CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: AN INDIRECT TREATMENT COMPARISON
Wang, J.
Patel, S.
Yang, H.
Chai, X.
Bi, S.
Du, M.
VALUE IN HEALTH, 2024, 27 (12)
[34] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
Vesole, David H.
Siegel, David Samuel DiCapua
Richter, Joshua Ryan
McNeill, Ann
Anand, Palka
Bednarz, Urszula
Ivanovski, Kristin
McBride, Laura
Raucci, Laura
Batra, Veena
Aleman, Adolfo
Sims, Taliah
Guerrero, Laura
Smith, Judith
Mato, Anthony R.
Bilotti, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[35] Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Morabito, Fortunato
Zamagni, Elena
Conticello, Concetta
Pavone, Vincenzo
Palmieri, Salvatore
Bringhen, Sara
Galli, Monica
Mangiacavalli, Silvia
Derudas, Daniele
Rossi, Elena
Ria, Roberto
Catalano, Lucio
Tacchetti, Paola
Mele, Giuseppe
Vincelli, Iolanda Donatella
Martino, Enrica Antonia
Vigna, Ernesto
Botta, Cirino
Bruzzese, Antonella
Mele, Anna
Pantani, Lucia
Rocchi, Serena
Garibaldi, Bruno
Cascavilla, Nicola
Ballanti, Stelvio
Tripepi, Giovanni
Frigeri, Ferdinando
Falcone, Antonetta Pia
Cangialosi, Clotilde
Reddiconto, Giovanni
Farina, Giuliana
Barone, Marialucia
Rizzello, Ilaria
Musto, Pellegrino
De Stefano, Valerio
Musso, Maurizio
Petrucci, Maria Teresa
Offidani, Massimo
Neri, Antonino
Di Renzo, Nicola
Di Raimondo, Francesco
Boccadoro, Mario
Cavo, Michele
Gentile, Massimo
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (03) : 178 - 189
[36] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Liu, Chia-Jen
Ghobrial, Irene M.
Bustoros, Mark
Reyes, Kaitlen
Hornburg, Kalvis
Badros, Ashraf Z.
Vredenburgh, James J.
Boruchov, Adam
Matous, Jeffrey V.
Caola, Aaron
Rivotto, Bradley
Savell, Alexandra
Henrick, Patrick
Paba-Prada, Claudia E.
Schlossman, Robert L.
Laubach, Jacob
Rosenblatt, Jacalyn
Yee, Andrew J.
Nadeem, Omar
Maegawa, Rodrigo O.
Jakubowiak, Andrzej
Usmani, Saad Z.
Bhutani, Manisha
Cappuccio, Joseph
Berrios, Brianna
Noonan, Kimberly
Zavidij, Oksana
Mouhieddine, Tarek H.
Boehner, Cody J.
Neuse, Carl-Jannes
Salem, Karma Ziad
Reidy, Mairead
Park, Jihye
Agius, Michael
Rahmat, Mahshid
Manier, Salomon
Bhutani, Divaya
Zonder, Jeffrey A.
Munshi, Nikhil
Auclair, Daniel
Anderson, Kenneth
Richardson, Paul
BLOOD, 2018, 132
[38] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Dingli, David
Go, Ronald S.
Warsame, Rahma
Kourelis, Taxiarchis
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
Wolfe, Eric
BLOOD, 2018, 132
[39] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Ghobrial, Irene M.
Badros, Ashraf Z.
Vredenburgh, James J.
Matous, Jeffrey
Caola, Aaron M.
Savell, Alexandra
Henrick, Patrick
Paba-Prada, Claudia E.
Schlossman, Robert L.
Laubach, Jacob P.
Rosenblatt, Jacalyn
Yee, Andrew
Wisch, Jeffrey S.
Farber, Charles M.
Maegawa, Rodrigo O.
Usmani, Saad Z.
Cappuccio, Joseph
Rivotto, Bradley
Noonan, Kimberly
Reyes, Kaitlen
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul
BLOOD, 2016, 128 (22)
[40] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Zimmerman, Todd
Raje, Noopur S.
Vij, Ravi
Reece, Donna
Berdeja, Jesus G.
Stephens, Leonor A.
McDonnell, Kathryn
Rosenbaum, Cara A.
Jasielec, Jagoda
Richardson, Paul G.
Gurbuxani, Sandeep
Nam, Jennifer
Severson, Erica
Wolfe, Brittany D.
Rosebeck, Shaun
Stefka, Andrew
Dytfeld, Dominik
Griffith, Kent
Jakubowiak, Andrzej
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →